The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Don Creighton
Advertisement
Articles by Don Creighton
The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Healthcare’s workforce has a scale problem, but new model is emerging
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
5